参仙乙肝灵联合替比夫定治疗HBeAg阳性慢性乙型肝炎随机平行对照研究  

ShenXianYiGanLing combined with Telbivudine for 60 cases of Patients with HBeAg Positive Chronic Hepatitis B Randomized Controlled Study

作　　者：胡珊珊[1] 孙克伟[2] 

机构地区：[1]湖南中医药大学,长沙410007 [2]湖南中医药大学第一附属医院,长沙410007

出　　处：《实用中医内科杂志》2012年第5期47-49,共3页Journal of Practical Traditional Chinese Internal Medicine

摘　　要：[目的]观察参仙乙肝灵联合替比夫定治疗HBeAg阳性慢性乙型肝炎疗效。[方法]使用随机平行对照方法,将60例门诊HBeAg阳性慢性乙型肝炎患者随机分两组。单用组30例替比夫定600mg口服,1次/d。联合组30例参仙乙肝灵片8粒/次,3次/d;替比夫定600mg口服,1次/d。均连续给药52周。治疗12周、24周、52周检测HBV DNA、乙型肝炎e抗原(HBeAg)、中医症候改善、肝功能指标变化及药物不良反应,随访1年,判定疗效。[结果]HBV-DNA阴转率及HBeAg/HBeAb血清转换率12周两组均无明显差异(P>0.05);24周、52周联合组均优于单用组(P<0.05);中医症候疗效联合组优于单用组(P<0.05);治疗12周、24周、52周两组肝功能均有明显改善(P<0.05),组间无显著差异(P>0.05);两组均未发现明显副作用。[结论]参仙乙肝灵联合替比夫定治疗HBeAg阳性慢性乙型肝炎优于单用替比夫定,可提高治疗慢性乙型肝炎的疗效。[ Objective ] To observe the effects of ShenXianYiGanLing combined with telbivudine in patients with HBeAg positive chronic hepatitis B. [ Methods ] 60 cases of HBeAg positive CHB were randomly divided into two groups. In combined group （30cases） , telbivudine was given 600 mg once a day and ShenXianYiGanLing 8 pieces of each time. three times a day. In telbivudine group （30 cases） , telbivudine was given alone.Clinical evaluation and laboratory detection were performed at the 12,24,52 weeks of the follow up period. [ Results] At 12 weeks, undetectable rates of serum HBV DNA in combination group and telbivudine group had no statistically significant difference （ P 〉 0.05 ） ; but at 24 weeks and 52 weeks, the two groups of comparisons difference had statistical significance （ P 〈 0. 05 ）. Seroconversion rates of HBeAgg/HBeAb in combination group and telbivudine group had no statistically significant difference at 12 weeks （ P 〉 0.05 ） , But the sero- conversion rates had statistical significance at 24 weeks and 52 weeks （P 〈 0.05 ）. The improved rates of Chinese medicine symptoms, the combined group were 96.67 % , the telbivudine group were 80.0 % （ P 〈 0.05 ）. Compared with untreatment, the normalization rates of ALT and AST in the two groups had statistically significant at 12 weeks, 24 weeks and 52 weeks（P 〈0.05）. There were no severe adverse reaction in both groups. [ Conclusion] The clinical effect of ShenXianYiGanLing combined with telbivudine for patients with HBeAg positive chronic hepatitis B was superior to telbivudine dipivoxil. ShenXianYiGanLing combined with telbivudine could enhance the effect of antivirus therapy for patients with chronic hepatitis B.

关 键 词：HBEAG阳性慢性乙型肝炎 参仙乙肝灵 替比夫定 中西医结合治疗 HBV-DNA阴转 HBeAg/HBeAb血清转换率 随机平行对照研究 

分 类 号：R256.43[医药卫生—中医内科学]